GlassScriptPhysician profile
Richard L Stern
NPI 1578562278
$2,170.41
in general payments reported to CMS, 2019-2025
15 companies · $427 in 2025
The $427 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $107 · 2021: $109 · 2022: $68.96 · 2023: $99.31 · 2024: $754 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $504.05 | 2019-2025 | |
| Abbvie INC. | $413.19 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $380.53 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| Janssen Biotech, INC. | $204.07 | 2019-2025 | Tremfya |
| Aurinia Pharma U.S., INC. | $163.71 | 2024 | Lupkynis |
| Glaxosmithkline, LLC. | $141.86 | 2019-2025 | Benlysta |
| Pfizer INC. | $134.21 | 2019-2024 | |
| Genentech USA, INC. | $60.80 | 2021-2024 | Actemra |
| Lilly USA, LLC | $46.04 | 2022-2024 | Taltz |
| Ani Pharmaceuticals, INC. | $33.55 | 2024 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $24.74 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.57 | 2024 | Ofev |
| Horizon Therapeutics Plc | $16.94 | 2021 | |
| Hospira, INC. | $14.21 | 2024 | |
| Zimmer Biomet Holdings, INC. | $13.94 | 2024 | Gps III Platelet Concentration System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.